Finoriq research workspace
Avalo Therapeutics, Inc. (AVTX) Historical Metrics
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for. Review AVTX fundamentals, ratios, and historical filing metrics on Finoriq.
Company Snapshot
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
- Company
- Avalo Therapeutics, Inc. (AVTX)
- Ticker
- AVTX
- Market Cap
- $967.7M
- Latest Price
- $18.41
- Industry
- Biotech & Pharma
Avalo Therapeutics, Inc. (AVTX) Current Valuation Metrics
Static valuation preview for Avalo Therapeutics, Inc. (AVTX). Market data retrieved 2026-07-09. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| P/SMarket cap divided by latest TTM revenue. | 17,774x | Revenue | TTM FY 2025 |
| Earnings YieldLatest TTM net income divided by market cap. | -8.1% | Net Income | TTM Q1 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -5.7% | Operating Cash Flow | TTM Q1 2026 |
| Price / BookMarket cap divided by stockholders' equity. | 15.3x | Stockholders' Equity | Q1 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.